<p><strong>Pediatric Use</strong>: Safety and effectiveness in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: Patients &gt; 75 years of age who received Prasugrel had an increased risk of fatal bleeding events (1.0%) compared to patients who received Clopidogrel (0.1%).<br />
<br />
<strong>Renal Impairment</strong>: No dosage adjustment is necessary for patients with renal impairment. There is limited experience in patients with end-stage renal disease.<br />
<br />
<strong>Hepatic Impairment</strong>: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.</p>